AEterna Zentaris (AEZS)
(Delayed Data from NSDQ)
$9.69 USD
-0.24 (-2.42%)
Updated May 31, 2024 03:46 PM ET
After-Market: $9.88 +0.19 (1.96%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
AEterna Zentaris Inc. [AEZS]
Reports for Purchase
Showing records 161 - 168 ( 168 total )
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
SOLID AACR DATA - POSITIVE ADVICE FROM EMA - CASH POSITION BOLSTERED
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
SOLID AACR DATA - POSITIVE ADVICE FROM EMA - CASH POSITION BOLSTERED
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Partner Keryx Commences Phase 3 Trial Evaluating Perifosine in Colorectal Cancer
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
4Q09 - PERIFOSINE IN PIVOTAL TRIALS - PHASE 3 ASSET SOLOREL TO DRIVE VALUE
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
R&R?s Week in Review: Oncology and Stem Cell Sectors
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R